SOLIGENIX INC (SNGX) Stock News

USA - NASDAQ:SNGX - US8342236044 - Common Stock

1.65 USD

+0.1 (+6.45%)

Last: 10/17/2025, 8:00:02 PM

1.64 USD

-0.01 (-0.61%)

After Hours: 10/17/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SNGX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Soligenix

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

10 days ago - By: Stocktwits

News Image

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

11 days ago - By: Soligenix, Inc.

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

18 days ago - By: Soligenix, Inc.

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

18 days ago - By: Soligenix, Inc.

Soligenix Announces Closing of $7.5 Million Public Offering

22 days ago - By: Benzinga - Mentions: CASI SSKN CRNX APLT ...

12 Health Care Stocks Moving In Friday's Intraday Session

22 days ago - By: Benzinga - Mentions: DRIO CLSD CRNX ORGO ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

22 days ago - By: Soligenix, Inc.

Soligenix Announces Pricing of $7.5 Million Public Offering

25 days ago - By: Soligenix, Inc.

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

a month ago - By: Soligenix, Inc.

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

2 months ago - By: Soligenix, Inc.

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Soligenix, Inc.

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

2 months ago - By: Soligenix, Inc.

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results